Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection. (BLOC-TAP)

Centre Hospitalier Universitaire de Saint Etienne

Status: Terminated

Conditions: Liver Cancer, Adult

Treatments: Drug: RopivacaIne chlorhydrate; Drug: Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02527577

A100140-28 (Other Identifier)

2009-017768-18 (EudraCT Number)

0908127

Details and patient eligibility

About

The indications liver cancer surgery currently booming due to the increase in surgical techniques and instruments for a more secure resection of liver tissue with a significant reduction in bleeding or surgical complications. This allowed to expand surgical indications in the most fragile patients so assuming optimized anesthetic care.

So far, the technique of analgesia reference to this surgery remains administration of morphine analgesia via a device controlled by the patient (PCA) for epidural analgesia is against-indicated because of induced bleeding disorders by surgery.

Rafi then McDonnell in 2007 have described a new technique of loco regional anesthesia, the abdomen of the Transversus Abdominis Plane (TAP) nerve block(TAP), which allows selective anesthesia of the abdominal wall. But parietal pain related muscular and nervous sagging surgical approach represent a significant share of post operative pain.

This study proposes an evaluation of the abdomen transverse blocks in hepatectomy.

Enrollment: 39 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• hepatectomy or segmentectomy

Exclusion criteria

• Sepsis uncontrolled current
• Overdose in anticoagulant during general anesthesia
• Thrombocytopenia <50 g / dl
• Severe renal impairment: Cockcroft <30 ml / min
• history of ventricular arrhythmia serious unexplained .*
• Allergy to local anesthetics of the amide
• Contraindication to remifentanil and morphine
• Hypovolemia

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

39 participants in 2 patient groups, including a placebo group

ropivacaïne chlorhydrate monohydrate

Experimental group

Treatment:

Drug: RopivacaIne chlorhydrate

placebo

Placebo Comparator group

Treatment:

Drug: Placebo